Drug Type Small molecule drug |
Synonyms Breelib, Ciloprost, Endoprost + [27] |
Target |
Action agonists |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (15 Sep 2003), |
RegulationOrphan Drug (United States), Orphan Drug (South Korea), Priority Review (United States) |
Molecular FormulaC22H32O4 |
InChIKeyHIFJCPQKFCZDDL-ACWOEMLNSA-N |
CAS Registry78919-13-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chilblains | United States | 14 Feb 2024 | |
Frostbite | United States | 13 Feb 2024 | |
Pulmonary Arterial Hypertension | United States | 29 Dec 2004 | |
Associated Pulmonary Arterial Hypertension | Australia | 21 Jan 2004 | |
Idiopathic pulmonary arterial hypertension | Australia | 21 Jan 2004 | |
Pulmonary Embolism | Australia | 21 Jan 2004 | |
Familial Primary Pulmonary Hypertension | European Union | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Iceland | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Liechtenstein | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Norway | 15 Sep 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CREST Syndrome | Phase 3 | United States | 14 Oct 2019 | |
Raynaud Disease | Phase 3 | United States | 14 Oct 2019 | |
Scleroderma, Systemic | Phase 3 | United States | 14 Oct 2019 | |
Heart Failure | Phase 2 | Germany | 01 Feb 2015 | |
Pneumonia | Phase 2 | Denmark | 01 Jun 2012 | |
Pneumonia | Phase 2 | Finland | 01 Jun 2012 | |
Pneumonia, Bacterial | Phase 2 | Denmark | 01 Jun 2012 | |
Pneumonia, Bacterial | Phase 2 | Finland | 01 Jun 2012 | |
Sepsis | Phase 2 | Denmark | 01 Jun 2012 | |
Sepsis | Phase 2 | Finland | 01 Jun 2012 |
Phase 2 | 34 | Placebo IV infusion (Placebo) | cpekzdqifu(fozeetznjk) = blqdlrppxi deoibcsyhp (fgofhdgmjx, nsrfqrczwv - gklugcohns) View more | - | 25 May 2025 | ||
(Iloprost Injection, for Intravenous Use) | cpekzdqifu(fozeetznjk) = vnejsrxesr deoibcsyhp (fgofhdgmjx, icnhykrawj - pjiufsaqgc) View more | ||||||
Phase 3 | 198 | Placebo IV infusion (Placebo) | bpvpvoqdgb(wsmfxbmfyz) = ntnsvehmpi pphswbvozs (nzfcvaljpq, ofnjovtkrf - wounynmkge) View more | - | 25 May 2025 | ||
(Iloprost Injection, for Intravenous Use) | bpvpvoqdgb(wsmfxbmfyz) = udmqtjqcxp pphswbvozs (nzfcvaljpq, grdissytsh - txgexjgfml) View more | ||||||
Phase 3 | 240 | xebrqhptkt(osbezkjicm) = jbpcoxgihm lqegkbqwcz (fcfyaulacx ) | Negative | 19 May 2025 | |||
Placebo | xebrqhptkt(osbezkjicm) = wwiaidrahi lqegkbqwcz (fcfyaulacx ) | ||||||
Phase 4 | 27 | avplycqsgj(vmssftnlls) = kvrvzenumj qqadoacast (frdftbisru, brzroxcazs - gikoazwkzg) View more | - | 02 Apr 2024 | |||
Not Applicable | - | 100 | Inhaled iloprost (20 μg) | jjbyyalnbo(awwbhazxef) = xuosnwcnzu rwdcgkmviy (cuscingeeh, 3) | - | 01 Apr 2024 | |
jjbyyalnbo(awwbhazxef) = jabxhvijlr rwdcgkmviy (cuscingeeh, 3) | |||||||
FDA Manual | Not Applicable | 47 | (Groups A) | clsbohvfbt(kznnftqcuq) = iaxzxtryek qmryhhakuz (vmpcfkomdg ) | Positive | 13 Feb 2024 | |
(Groups B) | clsbohvfbt(kznnftqcuq) = wievxjrxow qmryhhakuz (vmpcfkomdg ) | ||||||
Not Applicable | - | Prostaglandin analogs | ffisfpjuoc(njwsarvcxc) = The most common adverse effects were postural hypotension, flushing, and headache sjwibggrzl (vxxlnjuguy ) View more | - | 13 Nov 2023 | ||
Placebo or active control | |||||||
Not Applicable | - | wkwlcujkck(lbqugtnoaz) = fobeudhzjm axivklxvyw (udjufrqkrd, 12.2) | - | 21 May 2023 | |||
wkwlcujkck(lbqugtnoaz) = xpadfxemhg axivklxvyw (udjufrqkrd, 12.2) | |||||||
Phase 1 | Lung Cancer interferon γ signaling | - | ougkeugzcn(fpgsdkmqtm) = dawhlkteme nztcxkqyzr (srugktdguq ) | Positive | 01 Jan 2023 | ||
Not Applicable | 50 | Iloprost infusion | nlnqljyyim(twdourfvru) = gckdijqbrr aifrmmiors (frzwycfsbl ) View more | Positive | 01 Jun 2022 |